Daniel P. O’Day
Also at Gilead Sciences Inc
About
Daniel P. O’Day is a seasoned executive with an extensive background in the pharmaceutical industry. Raised with a strong academic foundation, he built his early career on the principles of science and business management, having earned his degrees in biology and business administration from prestigious institutions.
Before joining GILD, he amassed over three decades of experience at Roche Pharmaceuticals, where he held various executive roles and was instrumental in steering the company's pharmaceutical and diagnostics divisions across North America, Europe, and Asia. His leadership journey at Roche also included pivotal board roles with companies such as Genentech and Flatiron Health.
Upon joining GILD in March 2019 as both Chairman and Chief Executive Officer, he brought his deep industry insights and commitment to innovation, driving the company’s strategy to address unmet medical needs and navigate evolving global healthcare challenges. His role has been central to enhancing the company’s pipeline and maintaining its leadership in the pharmaceutical market.
In addition to his executive duties at GILD, he serves as the Board Chair for the Pharmaceutical Research and Manufacturers of America (PhRMA), underscoring his influential presence in shaping industry standards and advancing healthcare initiatives.
$GILD Performance Under Daniel P. O’Day
Past Roles
| Organization | Role | Date Range | Details |
|---|---|---|---|
| Roche Pharmaceuticals | Chief Executive Officer | Before March 2019 | Held various executive positions for over three decades across North America, Europe, and Asia |
| Roche Pharmaceuticals | Member, Corporate Executive Committee | N/A | Served as a member during his tenure with no specific dates provided |
| Genentech | Board Member | N/A | Role held as part of his involvement with several public and private boards |
| Flatiron Health | Board Member | N/A | Role held as part of his involvement with several public and private boards |
| Foundation Medicine | Board Member | N/A | Role held as part of his involvement with several public and private boards |
External Roles
| Organization | Role | Date Range | Details |
|---|---|---|---|
| Pharmaceutical Research and Manufacturers of America (PhRMA) | Board Chair | N/A | Current active role |
| Galapagos NV | Board Member | N/A | In connection with its partnership with Gilead |
Fixed Compensation
| Component Name | Amount | Payment Schedule | Additional Details |
|---|---|---|---|
| Salary | $1,740,962 | Annually | Fixed annual salary |
| Company Contributions to Deferred Compensation Plan | $750,000 | Annual installments (final installment of a 5-year agreement) | Compensation for pension benefits forfeited with previous employer |
| Insurance Premiums | $7,482 | Annually | Life insurance premiums |
| Perquisites and Other Personal Benefits | $1,192,990 | Annually | Includes corporate aircraft use ($233,596 ), personal security services ($166,859 ), corporate automobiles use ($28,283 ) and executive digital protection ($7,000 ) |
Performance Compensation
Performance Shares
| Metric & Details | Value | Citations |
|---|---|---|
| Performance Share Type | Relative TSR Tranche & Revenue Tranche (50% weight each) | |
| Performance Period (Relative TSR) | March 1, 2023 - December 31, 2025 | |
| 2023 Revenue Goal (Revenue Tranche) | $26.5 billion | |
| Threshold Shares | 3,155 shares | |
| Target Shares | 58,514 shares | |
| Maximum Shares | 117,028 shares | |
| Grant Date | March 10, 2023 | |
| Grant Date Fair Value | $4,999,868 | |
| Vesting Condition | Must remain employed through corresponding Relative TSR-based and Revenue-based Awards Certification Dates |
Corporate Bonus (Non-Equity Incentive Plan)
| Metric & Details | Value | Citations |
|---|---|---|
| Target Corporate Bonus | $2,625,000 | |
| Maximum Bonus | $5,250,000 | |
| Base Salary | $1,750,000 | |
| Target Incentive Opportunity | 150% of base salary | |
| Total Award Value | $4,036,200 | |
| Performance Factor | 124% (tied to corporate performance) | |
| Performance Metrics | 100% corporate performance; specific quantitative metrics not provided | |
| Vesting/Conditions | No detailed vesting schedule provided |